Benzaiten Pharma Private Limited's ambitious Drug Intermediates Manufacturing Unit Project in Pyraram, Yadadri Bhuvanagiri district, Telangana, signifies a pivotal stride in the state's pharmaceutical domain. With a substantial investment of 22 crores, the project is slated to yield 100 tonnes per month (TPM) of crucial drug intermediates, playing a pivotal role in bolstering India's pharmaceutical self-reliance.
The endeavor aims to curtail reliance on imported drug intermediates, ensuring consistent and cost-effective access to vital pharmaceutical components. By facilitating the production of essential drug intermediates domestically, Benzaiten Pharma's initiative is poised to streamline and fortify the country's pharmaceutical supply chain.
The project's advantages extend beyond bolstering drug production efficiency. Its ripple effect is expected to catalyze Telangana's pharmaceutical industry growth, enticing further investments and fostering a conducive ecosystem for the sector's expansion. Simultaneously, the project forecasts employment opportunities, particularly for skilled professionals in the pharmaceutical and chemical sectors, contributing to regional economic development.
As Benzaiten Pharma's project gears up to propel Telangana's pharmaceutical prowess, its focus on local production of critical drug intermediates embodies a strategic move towards pharmaceutical self-sufficiency, envisaging far-reaching benefits for the state's industrial and economic landscape.
As on January, 2024. Project has gotten approvals. All approvals were granted. By January 2024, project construction will begin.
News by Rahul Yelligetti